Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

被引：0
|
作者：
Johnson, N. [1 ,2 ]
Bentley, J. [1 ]
Wang, L-Z [1 ]
Newell, D. R. [1 ]
Robson, C. N. [1 ]
Shapiro, G. I. [2 ]
Curtin, N. J. [1 ]
机构：
[1] Newcastle Univ, Northern Inst Canc Res, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, England
[2] Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA
来源：
BRITISH JOURNAL OF CANCER | 2024年
关键词：
D O I：
10.1038/s41416-024-02813-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：955 / 955
页数：1
相关论文
共 50 条
  • [1] Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
    N Johnson
    J Bentley
    L-Z Wang
    D R Newell
    C N Robson
    G I Shapiro
    N J Curtin
    British Journal of Cancer, 2010, 102 : 342 - 350
  • [2] Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
    Johnson, N.
    Bentley, J.
    Wang, L-Z
    Newell, D. R.
    Robson, C. N.
    Shapiro, G. I.
    Curtin, N. J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (02) : 342 - 350
  • [3] The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications
    Wesierska-Gadek, Jozefa
    Kramer, Matthias P.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (12) : 1611 - 1628
  • [4] Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
    Yamasaki, Fumiyuki
    Zhang, Dongwei
    Bartholomeusz, Chandra
    Sudo, Tamotsu
    Hortobagyi, Gabriel N.
    Kurisu, Kaoru
    Ueno, Naoto T.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (08) : 2168 - 2177
  • [5] Cyclin-dependent kinase 2 regulates androgen receptor activity in estrogen receptor negative breast cancer
    Proctor, Luke A.
    Hanson, Adrienne R.
    Butler, Miriam S.
    Tilley, Wayne D.
    Moore, Nicole L.
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [6] Cyclin-dependent kinase 1 and 2 activity as prognostic markers in early breast cancer
    van Nes, J. G. H.
    Smit, V. T. H. B. M.
    Putter, H.
    Kuppen, P. J.
    Kim, S. J.
    Masuda, N.
    Inaji, H.
    Yoshidome, K.
    Tsujimoto, M.
    Akiyama, F.
    Tsukamoto, F.
    Ishihara, H.
    Noguchi, S.
    van de Velde, C. J. H.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S254 - S254
  • [7] Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells
    Rodriguez, Benjamin A. T.
    Weng, Yu-I
    Liu, Ta-Ming
    Zuo, Tao
    Hsu, Pei-Yin
    Lin, Ching-Hung
    Cheng, Ann-Lii
    Cui, Hengmi
    Yan, Pearlly S.
    Huang, Tim H-M.
    CARCINOGENESIS, 2011, 32 (06) : 812 - 821
  • [8] MicroRNA-424 serves an anti-oncogenic role by targeting cyclin-dependent kinase 1 in breast cancer cells
    Xie, Dan
    Song, Hongming
    Wu, Tianqi
    Li, Dengfeng
    Hua, Kaiyao
    Xu, Hui
    Zhao, Bingkun
    Wu, Chenyang
    Hu, Jiashu
    Ji, Changle
    Deng, Yijun
    Fang, Lin
    ONCOLOGY REPORTS, 2018, 40 (06) : 3416 - 3426
  • [9] Inhibition of G(1) cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A(2)
    Gorospe, M
    Liu, YS
    Xu, QB
    Chrest, FJ
    Holbrook, NJ
    MOLECULAR AND CELLULAR BIOLOGY, 1996, 16 (03) : 762 - 770
  • [10] Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells
    Yenugonda, Venkata Mahidhar
    Deb, Tushar B.
    Grindrod, Scott C.
    Dakshanamurthy, Sivanesan
    Yang, Yonghong
    Paige, Mikell
    Brown, Milton L.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (08) : 2714 - 2725
12345